Wide molecular analysis of PanNET revealed that only MGMT promoter methylation seemed to correlate with Temozolomide response

#3804

Introduction: Temozolomide (TMZ) is an alkylating agent and is widely used in the treatment of PanNET. So far, only the MGMT status, defined by its immunohistochemical (IHC) expression or its promoter methylation, has been proposed as predictor of response to TMZ, but its value remains controversial.

Aim(s): to identify predictive markers of response to TMZ in PanNET.

Materials and methods: We collected PanNET tissue samples from 26 patients who received TMZ treatment from 3 ENETS CoEs. Patients were divided for comparison in poor responder (n=5, PFS<10), intermediate (n=10) and excellent responder (n=11, PFS>24 months) based on Progression Free Survival (PFS). We performed a large molecular analysis with an NGS DNA panel, DNA methylation (Infinium MethylationEPIC Bead Chip) and targeted transcriptome (Nanostring). MGMT methylation status was predicted using a regression model based on two probes.

Conference:

Presenting Author: Marinoni I

Authors: Cives M, Kirchner P, Palmirotta R, Lauricella E, de Mestier L,

Keywords: PanNET, Temozolomide, MGMT,